Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:NLTX
- CUSIP: N/A
- Web: capricor.com
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -416.28%
- Return on Assets: -89.63%
Frequently Asked Questions for Capricor Therapeutics (NASDAQ:NLTX)
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), BeiGene (BGNE), GW Pharmaceuticals PLC (GWPH) and Agios Pharmaceuticals (AGIO).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board
- Linda Marban Ph.D., President, Chief Executive Officer, Director
- Leland J. Gershell M.D. Ph.D., Chief Financial Officer, Principal Financial Officer
- Karen G. Krasney J.D., Executive Vice President, General Counsel
- Anthony Bergmann, Principal Accounting Officer, Vice President - Finance
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development
- Deborah Ascheim M.D., Chief Medical Officer
How do I buy Capricor Therapeutics stock?
Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
MarketBeat Community Rating for Capricor Therapeutics (NASDAQ NLTX)MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Capricor Therapeutics stock can currently be purchased for approximately $0.08.
Consensus Ratings for Capricor Therapeutics (NASDAQ:NLTX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Capricor Therapeutics (NASDAQ:NLTX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Capricor Therapeutics (NASDAQ:NLTX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Capricor Therapeutics (NASDAQ:NLTX)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $0.00 EPS
Dividend History for Capricor Therapeutics (NASDAQ:NLTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Capricor Therapeutics (NASDAQ:NLTX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Capricor Therapeutics (NASDAQ:NLTX)
Latest Headlines for Capricor Therapeutics (NASDAQ:NLTX)
No headlines for this company have been tracked by MarketBeat.com
Capricor Therapeutics (NLTX) Chart for Monday, July, 24, 2017